The present invention comprises one or more pharmaceutically acceptable excipients, pharmaceutically active compounds capable of reducing the amount of inflammatory neutrophil products on the ophthalmic surface, and optionally steroids, anti-inflammatory. Provided are ophthalmic preparations essentially consisting of a second pharmaceutically active compound selected from the group consisting of agents, mucolytic agents and combinations thereof. In particular, in the present invention, pharmaceutically active compounds are used for eye discomfort, mucosal cell aggregates / debris in tear film, symblepharon adhesion formation, palpebral shortening, palpebral margin / conjunctival keratosis, corneal angiogenesis. / Provided is an ophthalmic preparation capable of treating a clinical condition selected from the group consisting of inflammatory ocular surface diseases and immunological ophthalmic surface diseases that can cause symptoms of pannus, subconjunctival fibrosis and herpes ocular diseases. The present invention also provides a method for diagnosing or monitoring ocular surface diseases. [Selection diagram] Fig. 11本発明は、1種以上の薬学的に許容可能な賦形剤と、眼表面上の炎症性好中球産物の量を減らすことができる薬学的に活性な化合物と、任意にステロイド、抗炎症剤、粘液溶解剤及びそれらの組み合わせからなる群から選択される第2の薬学的に活性な化合物とから本質的になる眼科製剤を提供する。特に、本発明は、薬学的に活性な化合物が、眼の不快感、涙液膜中の粘膜細胞凝集体／デブリ、瞼球癒着形成、円蓋短縮、眼瞼縁／結膜角化、角膜血管新生／パンヌス、結膜下線維症及びヘルペス性眼疾患の症状を引き起こし得る炎症性眼表面疾患及び免疫学的眼表面疾患からなる群から選択される臨床状態を治療することができる眼科製剤を提供する。本発明はまた、眼表面疾患を診断又は監視する方法を提供する。【選択図】図11
